FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
FDA will delay its decision regarding the new drug application for panobinostat.
Novartis announced on Nov. 25, 2014 that FDA extended its Priority Review period by up to three months for its new drug application (NDA) of LBH589 (panobinostat) in combination with Velcade (bortezomib) and dexamethasone for patients with previously treated multiple myeloma.
This announcement follows the decision by an Oncologic Drugs Advisory Committee (ODAC) to vote against recommending approval of the drug earlier this month. Concern stemmed from the observed side effects of panobinostat during the PANORAMA-1 trial and the fact that more patients deaths within 30 days of treatment occurred more frequently in the panobinostat arm compared with placebo. Onclive reported that members of the advisory board did not see an overall survival benefit.
Although Priority Review reduced the standard 12-month review period to eight months, three additional months will be tacked onto the time it will take for FDA to reach a conclusion about the product.
Panobinostat is a pan-deacetylase inhibitor that if approved, could be a first-in-class treatment for patients with relapsed or relapsed and refractory multiple myeloma, according to Novartis. It is an oral, anticancer epigenetic regulator that is thought to inhibit multiple enzymes that cancer cells need to grow and survive. Histone deacetylase inhibitors have historically been used in psychiatry and neurology as mood stabilizers and anti-epileptics.
In a briefing to FDA on panobinostat prior to FDA’s decision to extend, Novartis said its investigational compound “offers a multifaceted approach for the inhibition of cancer cell proliferation and survival” through its effects on histone acetylation and gene expression, as well as on the oncogenic function of non-histone proteins such as Hsp90. "We are committed to working with the FDA as they continue to review the LBH589 NDA," said Alessandro Riva, MD, global head of oncology development and medical affairs, Novartis Oncology, in a press release.
SOURCES:
Novartis
http://www.novartis.com/newsroom/media-releases/en/2014/1873858.shtmlhttp://www.novartis.com/newsroom/media-releases/en/2014/1869569.shtml
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
